对于性结肠炎的新兴口服药物选择
Silvia Salvatori1,2, Benedetto Neri1,2, Irene Marafini1,2
1Gastroenterology Unit, Policlinico Universitario Tor Vergata, Rome, Italy.
Expert opinion on emerging drugs
|September 5, 2023
概括
新的口服药物为没有对当前治疗反应的性结肠炎 (UC) 患者提供了希望. 研究正在探索新的小分子疗法,以提高管理中度至重度UC的疗效和安全性.
科学领域:
- 胃肠病学和药理学 胃肠病学和药理学
- 药物开发和临床试验
背景情况:
- 现有的性结肠炎 (UC) 治疗方法对三分之一患有中度至重度疾病的患者无效.
- 许多UC患者经历了不良药物反应,需要新的治疗方法.
研究的目的:
- 审查目前正在临床试验中的或即将进入临床的性结肠炎 (UC) 的新兴口服药物.
- 为提供UC管理口服药物治疗的最新进展的概述.
主要方法:
- 在PubMed.com上进行了系统的文献搜索.
- 关键词包括"口服药物性结肠炎"",性结肠炎临床试验"和"UC阶段2和3试验".
- 排除在外的包括病例报告,病例系列,第一期和第四期研究,以及对已经批准的治疗方法的研究.
主要成果:
- 未来的UC治疗可能涉及多种小分子口服药物.
- 这些新型化合物表现出不同的疗效和安全性,甚至在同一类药物中.
结论:
- 预测患者对新的口服UC疗法的反应对于优化治疗结果至关重要.
- 个性化医疗方法,包括治疗前患者分层,可以提高疗效,安全性和资源配置.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
551
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
551
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
493
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
493
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
149
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
149
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195


